Skip to main content

Table 3 Immunoexpression of SOX10 protein in various pediatric CNS tumors

From: Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation

Tumor entity

> 75%

25–74%

1–24%

Negative

CNS neuroblastoma with FOXR2 activation (n = 20)

100%

0

0

0

Pediatric glioblastoma with G34 mutation (n = 25)

0

0

0

100%

Pediatric glioblastoma; MYCN (n = 20)

0

0

0

100%

Supratentorial ependymoma; RELA fusion (n = 40)

0

0

0

100%

Diffuse midline glioma, H3 K27-altered (n = 30)

0

40%

30%

30%

Pediatric glioblastoma, RTKI (pGBM_MID; n = 30)

25%

35%

20%

20%

Pediatric glioblastoma, RTKIII (n = 12)

0

0

0

100%

Adult glioblastoma, IDH-wildtype (n = 40)

0

20%

40%

40%

Adult glioblastoma; IDH-mutant (n = 20)

10%

30%

40%

20%

Anaplastic oligodendroglioma, IDH-mutant (n = 20)

10%

40%

30%

20%

Embryonal tumor with multilayered rosettes (n = 30)

0

0

0

100%

Atypical teratoid/rhabdoid tumor (n = 20)

0

0

0

100%

CNS neuroepithelial tumor; MN1-altered (n = 18)

0

0

0

100%

CNS neuroepithelial tumor; BCOR-altered (n = 8)

0

0

0

100%

CNS neuroepithelial tumor; CIC-altered (n = 5)

0

0

0

100%

Intracranial Ewing sarcoma (n = 4)

0

0

0

100%

Diffuse leptomeningeal glioneuronal tumor (n = 5)

0

0

0

100%